Hanall Biopharma Statistics

Total Valuation

Hanall Biopharma has a market cap or net worth of KRW 1.62 trillion. The enterprise value is 1.59 trillion.

Market Cap	1.62T
Enterprise Value	1.59T

Important Dates

The next estimated earnings date is Friday, March 7, 2025.

Earnings Date	Mar 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Hanall Biopharma has 50.71 million shares outstanding. The number of shares has increased by 0.02% in one year.

Current Share Class	n/a
Shares Outstanding	50.71M
Shares Change (YoY)	+0.02%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	0.21%
Owned by Institutions (%)	18.52%
Float	34.49M

Valuation Ratios

PE Ratio	n/a
Forward PE	107.67
PS Ratio	12.03
PB Ratio	9.43
P/TBV Ratio	12.93
P/FCF Ratio	228.40
P/OCF Ratio	n/a
PEG Ratio	2.33

Financial Ratio History

Enterprise Valuation

EV / Earnings	-252.76
EV / Sales	11.84
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	224.76

Financial Position

The company has a current ratio of 2.86, with a Debt / Equity ratio of 0.01.

Current Ratio	2.86
Quick Ratio	1.64
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	0.21
Interest Coverage	-97.92

Financial Efficiency

Return on equity (ROE) is -3.41% and return on invested capital (ROIC) is -2.33%.

Return on Equity (ROE)	-3.41%
Return on Assets (ROA)	-1.91%
Return on Capital (ROIC)	-2.33%
Revenue Per Employee	434.45M
Profits Per Employee	-20.35M
Employee Count	309
Asset Turnover	0.59
Inventory Turnover	2.14

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.14% in the last 52 weeks. The beta is 0.84, so Hanall Biopharma's price volatility has been lower than the market average.

Beta (5Y)	0.84
52-Week Price Change	-7.14%
50-Day Moving Average	40,134.00
200-Day Moving Average	36,711.00
Relative Strength Index (RSI)	36.32
Average Volume (20 Days)	532,077

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Hanall Biopharma had revenue of KRW 134.24 billion and -6.29 billion in losses. Loss per share was -124.78.

Revenue	134.24B
Gross Profit	68.88B
Operating Income	-6.93B
Pretax Income	-7.22B
Net Income	-6.29B
EBITDA	-3.86B
EBIT	-6.93B
Loss Per Share	-124.78

Full Income Statement

Balance Sheet

The company has 27.22 billion in cash and 1.47 billion in debt, giving a net cash position of 25.76 billion or 507.89 per share.

Cash & Cash Equivalents	27.22B
Total Debt	1.47B
Net Cash	25.76B
Net Cash Per Share	507.89
Equity (Book Value)	171.36B
Book Value Per Share	3,379.10
Working Capital	56.05B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 8.83 billion and capital expenditures -1.76 billion, giving a free cash flow of 7.07 billion.

Operating Cash Flow	8.83B
Capital Expenditures	-1.76B
Free Cash Flow	7.07B
FCF Per Share	139.45

Full Cash Flow Statement

Margins

Gross margin is 51.31%, with operating and profit margins of -5.16% and -4.68%.

Gross Margin	51.31%
Operating Margin	-5.16%
Pretax Margin	-5.38%
Profit Margin	-4.68%
EBITDA Margin	-2.87%
EBIT Margin	-5.16%
FCF Margin	5.27%

Dividends & Yields

Hanall Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.02%
Shareholder Yield	-0.02%
Earnings Yield	-0.39%
FCF Yield	0.44%

Stock Splits

The last stock split was on April 28, 2006. It was a forward split with a ratio of 10.

Last Split Date	Apr 28, 2006
Split Type	Forward
Split Ratio	10

Scores

Hanall Biopharma has an Altman Z-Score of 26.85.

Altman Z-Score	26.85
Piotroski F-Score	n/a